Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-2: epcoritamab + rituximab + lenalidomide versus chemoimmunotherapy in previously untreated follicular lymphoma
CTR20243120Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of epcoritamab, rituximab, lenalidomide in follicular lymphoma (FL), sponsored by AbbVie Inc.. Started Dec 2024; status: active.
02
Drugs
epcoritamabrituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20243120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243120.